Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Market Definition and Overview
3. Executive Summary
3.1. Market Snippet by Drug
3.2. Market snippet by Technology
3.3. Market Snippet by End-User
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising usage of 3D printing in the medical industries
4.1.1.2. Increasing adoption of personalized drugs
4.1.2. Restraints
4.1.2.1. Adverse effects of 3D printed drugs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Regulatory Analysis
5.3. Pricing Analysis
5.4. Supply Chain Analysis
5.5. Product Innovations
5.6. Unmet Needs
6. By Drug
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Segment
6.3. Market Attractiveness Index, By Drug Segment
6.3.1. Spritam *
6.3.1.1. Introduction
6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
6.3.2. Others
7. By Technology
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
7.3. Market Attractiveness Index, By Technology Segment
7.3.1.
7.3.1.1. Inkjet printing*
7.3.1.1.1. Introduction
7.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
7.3.1.2. Fused deposition modelling (FDM)
7.3.1.3. Stereolithography (SLA)
7.3.1.4. Others
8. By End-User
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
8.3. Market Attractiveness Index, By End-User Segment
8.3.1.
8.3.1.1. Hospitals*
8.3.1.1.1. Introduction
8.3.1.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
8.3.1.2. Clinics
8.3.1.3. Research Laboratories
8.3.1.4. Others
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. Australia
9.5.6.5. Rest of Asia Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Aprecia Pharmaceuticals*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Highlights
11.1.4. Financial Overview
11.2. GlaxoSmithKline Plc.
11.3. Hewlett Packard Caribe, BV, LLC
11.4. FabRx Ltd. (*LIST NOT EXHAUSTIVE)
12. DataM Intelligence
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us